Indevus/Pliva Sanctura Will Enter Overactive Bladder Market In Third Quarter
Executive Summary
Indevus/Pliva's Sanctura will enter the overactive bladder market during the third quarter
You may also be interested in...
Indevus/Pliva Sanctura clears FDA
Indevus/Pliva's Sanctura (trospium) clears FDA May 28 for treatment of overactive bladder. Product will be launched in third quarter. Sanctura is first new molecular entity approved for overactive bladder since Pharmacia's Detrol (tolterodine) in 1998 [Editor's Note: More coverage of the Sanctura approval appears in 1"The Pink Sheet" DAILY. Visit our website, www.ThePinkSheetDAILY.com, to sign up for a free trial.]....
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials